Trial · NCT01797965
Adverse events1,304
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,304
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Lymphadenopathy | Blood and lymphatic system disorders | IFN β-1a 30 µg (301)/DAC HYP 150 mg (303) | 47 | 597 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | DAC HYP 150 mg (301) /DAC HYP 150 mg (303) | 71 | 606 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | DAC HYP 150 mg (302) /DAC HYP 150 mg (303) | 3 | 70 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | DAC HYP 150 mg (203) /DAC HYP 150 mg (303) | 7 | 227 | |
| other | Diarrhoea | Gastrointestinal disorders | IFN β-1a 30 µg (301)/DAC HYP 150 mg (303) | 42 | 597 | |
| other | Diarrhoea | Gastrointestinal disorders | DAC HYP 150 mg (301) /DAC HYP 150 mg (303) | 35 | 606 | |
| other | Diarrhoea | Gastrointestinal disorders | DAC HYP 150 mg (302) /DAC HYP 150 mg (303) | 2 | 70 | |
| other | Diarrhoea | Gastrointestinal disorders | DAC HYP 150 mg (203) /DAC HYP 150 mg (303) | 10 | 227 | |
| other | Toothache | Gastrointestinal disorders | IFN β-1a 30 µg (301)/DAC HYP 150 mg (303) | 17 | 597 | |
| other | Toothache | Gastrointestinal disorders | DAC HYP 150 mg (301) /DAC HYP 150 mg (303) | 14 | 606 | |
| other | Toothache | Gastrointestinal disorders | DAC HYP 150 mg (302) /DAC HYP 150 mg (303) | 4 | 70 | |
| other | Toothache | Gastrointestinal disorders | DAC HYP 150 mg (203) /DAC HYP 150 mg (303) | 3 | 227 | |
| other | Fatigue | General disorders | IFN β-1a 30 µg (301)/DAC HYP 150 mg (303) | 40 | 597 | |
| other | Fatigue | General disorders | DAC HYP 150 mg (301) /DAC HYP 150 mg (303) | 41 | 606 | |
| other | Fatigue | General disorders | DAC HYP 150 mg (302) /DAC HYP 150 mg (303) | 3 | 70 | |
| other | Fatigue | General disorders | DAC HYP 150 mg (203) /DAC HYP 150 mg (303) | 4 | 227 | |
| other | Pyrexia | General disorders | IFN β-1a 30 µg (301)/DAC HYP 150 mg (303) | 45 | 597 | |
| other | Pyrexia | General disorders | DAC HYP 150 mg (301) /DAC HYP 150 mg (303) | 43 | 606 | |
| other | Pyrexia | General disorders | DAC HYP 150 mg (302) /DAC HYP 150 mg (303) | 3 | 70 | |
| other | Pyrexia | General disorders | DAC HYP 150 mg (203) /DAC HYP 150 mg (303) | 7 | 227 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01797965/events